Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Pipeline Review, H2 2017’, provides in depth analysis on Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology under development targeting Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aerie Pharmaceuticals Inc

Aptose Biosciences Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Celon Pharma SA

Concert Pharmaceuticals Inc

CTI BioPharma Corp

Eli Lilly and Co

Genentech Inc

Incyte Corp

Japan Tobacco Inc

Nerviano Medical Sciences Srl

Novartis AG

NS Pharma Inc

Simcere Pharmaceutical Group

Theravance Biopharma Inc

Vectura Group Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Overview 8

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 15

Products under Development by Universities/Institutes 21

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Therapeutics Assessment 23

Assessment by Mechanism of Action 23

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Companies Involved in Therapeutics Development 27

Aerie Pharmaceuticals Inc 27

Aptose Biosciences Inc 27

AstraZeneca Plc 27

Bristol-Myers Squibb Co 28

Celon Pharma SA 28

Concert Pharmaceuticals Inc 29

CTI BioPharma Corp 29

Eli Lilly and Co 30

Genentech Inc 31

Incyte Corp 31

Japan Tobacco Inc 32

Nerviano Medical Sciences Srl 33

Novartis AG 33

NS Pharma Inc 34

Simcere Pharmaceutical Group 34

Theravance Biopharma Inc 35

Vectura Group Plc 35

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Drug Profiles 37

APL-581 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

AR-13154 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

AZD-1480 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

baricitinib - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

BVB-808 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

CHZ-868 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

CPL-407105 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

CTP-543 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

fedratinib - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

jaktinib - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

JTE-052 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

MA-2014 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

NMSP-113 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

NMSP-953 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

NS-018 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

pacritinib - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

ruxolitinib phosphate - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

SAR-317461 - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

Small Molecules to Inhibit JAK2 for Cancer - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

TD-1473 - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

TD-3504 - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

TG-02 - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

VR-588 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Dormant Products 113

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Discontinued Products 117

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Product Development Milestones 119

Featured News & Press Releases 119

Oct 30, 2017: Lilly to Present New Data on its Anti-inflammatory Drug Candidate Baricitinib at ACR/ARHP Annual Meeting 119

Oct 19, 2017: Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent 123

Sep 14, 2017: Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis 123

Sep 11, 2017: Lilly to Present New Data for Olumiant (baricitinib) at the European Academy of Dermatology and Venereology (EADV) Annual Congress 124

Sep 11, 2017: Olumiant is accepted for restricted use within NHS Scotland 124

Aug 30, 2017: Lilly To File Baricitinib Resubmission To U.S. FDA Before End Of January 2018 125

Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis 125

Aug 01, 2017: CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib 127

Jul 25, 2017: Lilly And Incyte Provide Update On Baricitinib 127

Jul 13, 2017: CTI BioPharma Announces European Medicines Agency Validation of Pacritinib Marketing Authorization Application for Patients with Myelofibrosis who have Thrombocytopenia 128

Jul 10, 2017: FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543 128

Jul 03, 2017: Japan Ministry Of Health, Labor And Welfare (MHLW) Grants Marketing Approval For Olumiant (Baricitinib) For The Treatment Of Rheumatoid Arthritis 129

Jun 29, 2017: NICE Recommends Lilly's Baricitinib (Olumiant) for the Treatment of Severe Rheumatoid Arthritis 129

Jun 16, 2017: New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017 130

Jun 13, 2017: Lilly To Present New Data On Olumiant (Baricitinib) In Rheumatoid Arthritis At The Annual European Congress Of Rheumatology (EULAR 2017) 131

Appendix 134

Methodology 134

Coverage 134

Secondary Research 134

Primary Research 134

Expert Panel Validation 134

Contact Us 134

Disclaimer 135

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14

Number of Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20

Number of Products under Investigation by Universities/Institutes, H2 2017 21

Products under Investigation by Universities/Institutes, H2 2017 22

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Stage and Route of Administration, H2 2017 25

Number of Products by Stage and Molecule Type, H2 2017 26

Pipeline by Aerie Pharmaceuticals Inc, H2 2017 27

Pipeline by Aptose Biosciences Inc, H2 2017 27

Pipeline by AstraZeneca Plc, H2 2017 28

Pipeline by Bristol-Myers Squibb Co, H2 2017 28

Pipeline by Celon Pharma SA, H2 2017 29

Pipeline by Concert Pharmaceuticals Inc, H2 2017 29

Pipeline by CTI BioPharma Corp, H2 2017 30

Pipeline by Eli Lilly and Co, H2 2017 30

Pipeline by Genentech Inc, H2 2017 31

Pipeline by Incyte Corp, H2 2017 32

Pipeline by Japan Tobacco Inc, H2 2017 33

Pipeline by Nerviano Medical Sciences Srl, H2 2017 33

Pipeline by Novartis AG, H2 2017 34

Pipeline by NS Pharma Inc, H2 2017 34

Pipeline by Simcere Pharmaceutical Group, H2 2017 35

Pipeline by Theravance Biopharma Inc, H2 2017 35

Pipeline by Vectura Group Plc, H2 2017 36

Dormant Products, H2 2017 113

Dormant Products, H2 2017 (Contd..1), H2 2017 114

Dormant Products, H2 2017 (Contd..2), H2 2017 115

Dormant Products, H2 2017 (Contd..3), H2 2017 116

Discontinued Products, H2 2017 117

Discontinued Products, H2 2017 (Contd..1), H2 2017 118

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 24

Number of Products by Stage and Routes of Administration, H2 2017 24

Number of Products by Stage and Molecule Type, H2 2017 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports